Smart-Money SignalDistribution · 35/100— Insiders are net sellers over 90 days (-$12.1M, 31 sales vs 10 buys)
Net Income-$126.5M
EPS$-1.43
Market Cap$7.2B
Price Performance
Historical data including institutional events
Company Profile
E
Eric Venker
CEO & Executive Director
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögrenâs disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease.
The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
